Clik here to view.
AstraZeneca reveals early data for oral PCSK9, touts PK edge over Merck’s drug
AstraZeneca has unveiled the early efficacy profile of its oral PCSK9 inhibitor in patients with high levels of “bad” cholesterol. One arm of the Phase 1 trial studied a dose of the drug, dubbed...
View ArticleClik here to view.
Merck returns to lucrative eye disease market in up to $3B deal for EyeBio
A decade after departing the ophthalmology drug market, Merck is launching a return to the field in a $1.3 billion upfront cash acquisition for Series A-stage EyeBio. Merck could dish out another $1.7...
View ArticleArcturus teases data from small trial of inhalable cystic fibrosis mRNA...
Arcturus Therapeutics has offered an early snapshot of its inhaled mRNA therapy’s effects in cystic fibrosis, building its case for a delivery technology designed to transport mRNA to the lung. The...
View ArticleIkena Oncology drops cancer asset, trims headcount to save cash
Ikena Oncology has hit another speed bump as it ends work on a Phase 1 oncology candidate and plans to slash its workforce by more than half. It’s the Boston biotech’s second round of pipeline and...
View ArticleClik here to view.
Bristol Myers pays $80M to license another Prothena neuroscience candidate
Bristol Myers Squibb is shelling out $80 million to Prothena for an exclusive global license for an early-stage neurodegenerative candidate, as the pharma giant continues to invest in its neuroscience...
View ArticleNew York startup raises $33M for stem cell-derived treatment to improve IVF
Women hoping to conceive through in vitro fertilization often undergo two weeks of grueling hormone injections to mature and collect eggs. A New York startup called Gameto hopes to dramatically reduce...
View ArticleInsmed, Merus announce public offerings; AI startup raises $13M seed round
Plus, news about AEON Biopharma, Bio-Thera and STADA: Insmed to raise $500M in public offering: The startup launched the offering after it revealed positive Phase 3 data in a lung disease called...
View ArticleClik here to view.
J&J's major depressive disorder drug hits endpoints in Phase 3 trial
Johnson & Johnson is continuing to build out its neuroscience pipeline with positive topline data for its experimental depression and insomnia drug in a late-stage trial. The drug, seltorexant, is...
View ArticleBiohaven’s autoimmune drug disappoints investors in study of healthy volunteers
In a closely watched readout, Biohaven’s autoimmune disease treatment led to a 37% reduction on average in levels of harmful antibodies at the highest reported dose. But the reduction was not as high...
View ArticleArrowhead touts separate Phase 2b wins for RNAi treatments in mixed...
Arrowhead Pharmaceuticals is mulling what’s next for a pair of RNA interference therapies after reporting positive data from separate mid-stage trials in mixed hyperlipidemia. As RNAi treatments, both...
View ArticleAmgen nabs FDA approval for first Soliris interchangeable biosimilar
The FDA approved Amgen’s monoclonal antibody Bkemv as the first interchangeable biosimilar for Alexion’s blockbuster Soliris to treat two types of rare blood diseases, the agency announced late...
View ArticleBioNTech to increase mRNA vaccine footprint in Africa with $145M investment
Moderna may be holding back its plans for mRNA vaccine production in Africa, but Germany’s BioNTech is filling in the space with an expanded partnership with the Coalition for Epidemic Preparedness...
View ArticleClik here to view.
Ori Biotech, Cytiva separately unveil tech to accelerate cell therapy production
Two manufacturing tech developers have independently detailed their own approaches that could improve the cost and timelines to make cell and gene therapies and CAR-T products. On Wednesday, Ori...
View ArticleClik here to view.
Company developing video games for ADHD announces sale
A digital therapeutics pioneer is merging with another digital health company as the field, once flush with venture cash, struggles to find its place. Akili Interactive, a public company that develops...
View ArticleLilly's Retevmo lands new accelerated approval for pediatric cancers
The FDA on Wednesday granted another accelerated approval to Eli Lilly’s cancer drug Retevmo, this time for pediatric patients age 2 and older with certain types of thyroid cancer and solid tumors with...
View ArticleClik here to view.
FDA approves Tris Pharma's non-stimulant pediatric ADHD liquid medication
The FDA approved Tris Pharma’s Onyda XR to treat ADHD in children who are at least 6 years old. It’s the first liquid non-stimulant ADHD drug approved in the US, the company announced Wednesday, and...
View ArticleDollar General pulls mobile clinic mentions from website, partner no longer...
Has Dollar General quit its brief foray into healthcare services? The discount store chain, which launched a mobile healthcare clinic partnership in January 2023, appears to have removed mentions of...
View ArticleClik here to view.
Insurance upstart Clover Health launches new business selling its tech,...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The Medicare-focused health insurer Clover Health has launched a new venture to sell its technology...
View ArticleImmunovant postpones batoclimab readouts, maps path forward for second FcRn drug
Immunovant has reshuffled plans for two of its anti-FcRn antibody drugs. The company has delayed clinical readouts by several months for its late-stage FcRn inhibitor, called batoclimab, on the heels...
View ArticleBridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial
BridgeBio released additional analyses of its Phase 3 study of acoramidis in ATTR-CM on Wednesday, spotlighting the link between serum transthyretin (TTR) levels and the drug’s long-term efficacy in...
View Article